加载中
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
前收盘价
US$1.58
−US$0.11 · -6.51%
盘前
US$1.51
−US$0.07 · -4.43%
10月13日 6:27 ET
盘中时间采用ET。市场数据可能有所延迟。
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
日内区间
当前US$1.58
52周区间
当前US$1.58
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
42
多空交织
风险
89
极高风险
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
日内区间
当前US$1.58
52周区间
当前US$1.58
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 72.34万 USD | — | — | — | — |
| 毛利 | −72.34万 USD | — | — | — | — |
| 研究与开发 | 4236.19万 USD | 1870.17万 USD | 581.95万 USD | 601.18万 USD | 293.14万 USD |
| 销售、一般及管理费用 | 1580.17万 USD | 1772.57万 USD | 785.23万 USD | 609.46万 USD | 491.63万 USD |
| 营业费用 | 5744.02万 USD | 3019.27万 USD | 3473.52万 USD | 1831.17万 USD | 784.77万 USD |
| 利息收入 | 188.39万 USD | 326.35万 USD | 10万 USD | 1.9万 USD | 3 USD |
| 利息支出 | — | 96.76万 USD | 90.63万 USD | 66.38万 USD | 76.75万 USD |
| 折旧和摊销 | 72.34万 USD | 29.86万 USD | 12.43万 USD | 11.5万 USD | 3.41万 USD |
| 营业利润 | −5816.36万 USD | −3019.27万 USD | −3473.52万 USD | −1831.17万 USD | −784.77万 USD |
| 净利润 | −5592.48万 USD | −2656.71万 USD | −3764.48万 USD | −1948.16万 USD | −852.22万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 659.49%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月24日 | 1:8 | — | — |
股票拆分 | 2023年9月8日 | 1:250 | — | — |
已生效 2026年8月24日
1:8
已生效 2023年9月8日
1:250
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
